Drug Type Monoclonal antibody |
Synonyms GR 1405, GR1405 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | Phase 3 | CN | 06 Jun 2022 | |
Advanced Triple-Negative Breast Carcinoma | Phase 2 | CN | 11 Jun 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 16 Sep 2019 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | 16 Sep 2019 | |
Lymphoma | IND Application | CN | 16 Nov 2017 |